至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Enteropathogenic Escherichia coli inhibits type I interferon- and RNase L-mediated host defense to disrupt intestinal epithelial cell barrier function

Infect Immun. 2015; 
Long TM, Nisa S, Donnenberg MS, Hassel BA.
Products/Services Used Details Operation
Gene Synthesis For cytokine treatment, Caco-2 cell monolayers were treated apically with IFN-␤ (PBL Assay Science, Piscataway, NJ) or IFN-␥ (Genscript, Piscataway, NJ) and TNF-␣ (InvivoGen, San Diego, CA) at the concentrations and times indicated prior to analysis of gene expres- sion, TEER, or EPEC infection. Get A Quote

摘要

Enteropathogenic Escherichia coli (EPEC) primarily infects children in developing countries and causes diarrhea that can be deadly. EPEC pathogenesis occurs through type III secretion system (T3SS)-mediated injection of effectors into intestinal epithelial cells (IECs); these effectors alter actin dynamics, modulate the immune response, and disrupt tight junction (TJ) integrity. The resulting compromised barrier function and increased gastrointestinal (GI) permeability may be responsible for the clinical symptoms of infection. Type I interferon (IFN) mediates anti-inflammatory activities and serves essential functions in intestinal immunity and homeostasis; however, its role in the immune response to enteric pa... More

关键词